Humalog patent?

Humalog is the brand name for insulin lispro, a rapid-acting insulin analog developed by Eli Lilly. There isn’t a single “Humalog patent.” Protection around Humalog has come from a bundle of patent families covering:

- The insulin lispro molecule itself (the amino-acid swap that defines lispro).
- Methods of making insulin lispro.
- Formulations and stabilizers for lispro insulin.
- Delivery devices and pens (and sometimes their kits).
- Specific high-concentration or premixed formulations and related methods.

What this means in practice:
- The core molecule patents for insulin lispro have expired in many major markets (roughly in the 2013–2016 window in the US and EU), which paved the way for biosimilars and generic competition.
- Some patents on formulations, devices, or manufacturing methods may still be in force in certain jurisdictions, potentially extending protection in those areas into the 2020s or beyond.
- In the US, biosimilar competition began with Admelog (insulin lispro) in 2017. There are other lispro biosimilars in various markets.

If you want precise details for a particular country (patent numbers, expiration dates, or which patents are still active), tell me the jurisdiction and whether you want core molecule patents, formulation/device patents, or all of the above. I can look up current records (USPTO, Google Patents, FDA Purple Book for biosimilars) and give you specific patent numbers and status.